Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04586530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial completedFinal enrollment: 194 participants (planned 220) · Eligibility criteria expanded, about 15 words · Secondary endpoints: details revised at 5 of 5 entriesShow 3 more changesShow less
Final enrollment: 194 participants (planned 220)
Eligibility criteria expanded, about 15 words
Secondary endpoints: details revised at 5 of 5 entries
MinorPrimary and study completion dates: May 31, 2026 to Jul 31, 2026v16
MinorRe-verified, no change to tracked fieldsv15
MinorTrial status: Recruiting to Active, Not RecruitingSite details revised at 2 of 2 sitesv14Show 1 more changeShow less
Site details revised at 2 of 2 sites
MinorEnrollment target: 200 to 220v13
Show 11 earlier versionsHide 11 earlier versions
NotablePrimary and study completion dates: May 31, 2025 to May 31, 2026Site contacts updated at 1 of 2 sites · Collaborators: 2 to 1v12Show 2 more changesShow less
MinorPrimary completion date: Dec 31, 2024 to May 31, 2025Site contacts updated at 2 of 2 sitesv10Show 1 more changeShow less
Site contacts updated at 2 of 2 sites
MinorSite contacts updated at 1 of 2 sitesv9
MinorRe-verified, no change to tracked fieldsv8
MinorSite contacts updated at 1 of 2 sitesv7
MinorStart date changed from estimate of Feb 2021 to Mar 18, 2021v6
NotableTrial status: Not Yet Recruiting to RecruitingSite details revised at 2 of 2 sitesv5Show 1 more changeShow less
Site details revised at 2 of 2 sites
MinorSite contacts updated at 2 of 2 sitesv4
NotableStart date: Dec 2020 to Feb 2021v3
NotableStart date: Oct 2020 to Dec 2020v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall purpose of this trial is to confirm the efficacy of Memory and Attention Adaptation Training (MAAT), a cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction among (female or male) breast cancer survivors. This is a multi-center, multi-clinician randomized control trial (MAAT vs. supportive therapy attention control condition). This trial will also evaluate a sub-sample of survivors pre-and post treatment with functional magnetic resonance imaging (fMRI) in a working memory task to evaluate pre-to-post treatment brain activation patterns to elucidate underlying mechanisms of clinical therapeutic change.